ARTICLE | Clinical News
Evofosfamide: Development discontinued
December 14, 2015 8:00 AM UTC
Threshold and partner Merck discontinued development of evofosfamide to treat STS after the open-label, international Phase III TH-CR-406/SARC021 trial in 640 patients with locally advanced unresectab...